The revision of the pharmaceutical legislation - it is time to act for nuclear medicine in Europe.
作者信息
Patt Marianne, Decristoforo Clemens, de Martini Amélie, Koole Michel, Oyen Wim J G, Kiss Oliver C
机构信息
Section Radiopharmacy, Department of Nuclear Medicine, University Hospital Augsburg, Augsburg, Germany.
Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
出版信息
Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):20-24. doi: 10.1007/s00259-023-06472-1.
Abstract
摘要
相似文献
1
The revision of the pharmaceutical legislation - it is time to act for nuclear medicine in Europe.药品立法的修订——欧洲核医学行动的时候到了。
Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):20-24. doi: 10.1007/s00259-023-06472-1.
2
Highlights of the annual meeting of The European Association of Nuclear Medicine, Lisbon 1992. How to increase the impact of nuclear medicine on clinical decision making.
Eur J Nucl Med. 1993 Mar;20(3):265-72. doi: 10.1007/BF00170011.
3
European system for reporting of adverse reactions and drug defects. Fourth report: 1986.欧洲药品不良反应和药物缺陷报告系统。第四次报告：1986年。
J Nucl Med Allied Sci. 1988 Jan-Mar;32(1):58-60.
4
Common uses of nonradioactive drugs in nuclear medicine.非放射性药物在核医学中的常见用途。
Am J Hosp Pharm. 1984 Jun;41(6):1189-93.
5
European system for reporting of adverse reactions and drug defects--second report 1982-1983.欧洲药品不良反应和药物缺陷报告系统——1982 - 1983年第二次报告
Nuklearmedizin. 1984 Apr;23(2):107-8.
6
[Global Trends Survey for Targeted Radionuclide Therapy].[靶向放射性核素治疗全球趋势调查]
Nihon Hoshasen Gijutsu Gakkai Zasshi. 2018 Dec;74(12):1443-1448. doi: 10.6009/jjrt.2018_JSRT_74.12.1443.
7
Comparison of nuclear cardiology in the United States and Europe.
Q J Nucl Med. 1996 Mar;40(1):27-34.
8
The QuADRANT study: current status and recommendations for improving uptake and implementation of clinical audit of medical radiological procedures in Europe-the nuclear medicine perspective.象限研究：欧洲医学放射程序临床审计的现状及提高采用率和实施情况的建议——核医学视角
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2576-2581. doi: 10.1007/s00259-023-06203-6.
9
Highlights of the annual meeting of the European Association of Nuclear Medicine, Lausanne 1993.1993年于洛桑召开的欧洲核医学协会年会亮点
Eur J Nucl Med. 1994 Feb;21(2):159-69. doi: 10.1007/BF00175765.
10
Nuclear medicine. Reflections in time.核医学。时光中的反思。
J Fla Med Assoc. 1995 Nov;82(11):749-50.
引用本文的文献
1
Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.革新前列腺癌检测：已获批的PSMA-PET显像剂的作用
Pharmaceuticals (Basel). 2025 Jun 17;18(6):906. doi: 10.3390/ph18060906.
2
Radiopharmaceutical small-scale preparation in Europe: will we be able to harmonize the situation?欧洲放射性药物的小规模制备：我们能够使情况协调一致吗？
EJNMMI Radiopharm Chem. 2024 Sep 5;9(1):64. doi: 10.1186/s41181-024-00281-z.
3
Guardians of precision: advancing radiation protection, safety, and quality systems in nuclear medicine.精准守护者：推进核医学中的辐射防护、安全及质量体系
Eur J Nucl Med Mol Imaging. 2024 May;51(6):1498-1505. doi: 10.1007/s00259-024-06633-w. Epub 2024 Feb 6.
本文引用的文献
1
[Lu]Lu-PSMA-617 (Pluvicto): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer.[镥]镥-PSMA-617（普卢维托）：首个获美国食品药品监督管理局批准用于治疗前列腺癌的放射治疗药物。
Pharmaceuticals (Basel). 2022 Oct 20;15(10):1292. doi: 10.3390/ph15101292.
2
EANM position on the in-house preparation of radiopharmaceuticals.欧洲核医学协会关于放射性药物内部制备的立场。
Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1095-1098. doi: 10.1007/s00259-022-05694-z.
3
EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy.EANM 关于理事会指令 2013/59/Euratom（基本安全标准）第 56 条的立场文件，该指令适用于核医学治疗。
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):67-72. doi: 10.1007/s00259-020-05038-9. Epub 2020 Oct 15.
4
Radionuclides: medicinal products or rather starting materials?放射性核素：是药品还是起始原料？
EJNMMI Radiopharm Chem. 2019 Aug 20;4(1):22. doi: 10.1186/s41181-019-0074-3.
5
European regulations for the introduction of novel radiopharmaceuticals in the clinical setting.欧洲关于新型放射性药物引入临床应用的法规。
Q J Nucl Med Mol Imaging. 2017 Jun;61(2):135-144. doi: 10.23736/S1824-4785.17.02965-X. Epub 2017 Jan 26.
6
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.68Ga-DOTA-酪氨酰3-奥曲肽PET在神经内分泌肿瘤中的应用：与生长抑素受体闪烁扫描及CT的比较
J Nucl Med. 2007 Apr;48(4):508-18. doi: 10.2967/jnumed.106.035667.
7
Peptide receptor radionuclide therapy.肽受体放射性核素治疗
Ann N Y Acad Sci. 2004 Apr;1014:234-45. doi: 10.1196/annals.1294.026.
8
"Clinical PET: its time has come?".《临床正电子发射断层显像：其时代已经来临？》
J Nucl Med. 1993 Jul;34(7):1132-3.
Zotero 插件